SCHEDULE: Shah Capital Vows to Vote Against Novavax Board Nominees

Shah Capital Management, a significant shareholder, has announced its intention to vote against Novavax's board nominees and executive compensation, citing value destruction and operational failures.

Summary

• Shah Capital Management, representing a 9.03% stake in Novavax, Inc., has formally notified the company's board of its intention to vote against the re-election of board nominees and the executive compensation package at the upcoming 2026 Annual Meeting.
• The decision stems from concerns over significant shareholder value destruction, chronic operational shortcomings, and alleged failures in fiduciary duty.
• Shah Capital highlights a 27% decline in share price from January 1, 2023, to March 31, 2026, and a 96% increase in shares outstanding during the same period, leading to substantial dilution.
• The letter also criticizes the company's revenue forecasts, particularly for Nuvaxovid, and the slow progress of the Sanofi partnership for a COVID/Influenza combo vaccine.
• Concerns are raised about insufficient cost-cutting measures, a pessimistic 2026 revenue forecast, and the structure of the executive team and board.
• Shah Capital advocates for aggressive cost reduction, aiming for combined SG&A and R&D expenses under $100 million for 2027, and suggests retiring outstanding convertible debt and considering opportunistic share buybacks.
• The firm also calls for governance changes, including a 30% reduction in the senior management team and a smaller, more experienced board of five members.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as strongly negative due to the explicit declaration of intent to vote against board nominees and executive compensation, backed by detailed criticisms of value destruction, operational failures, and poor financial performance.

Positives

• Novavax possesses a strong pipeline including Covid-Influenza Combo (CIC), Shingles, and C-Diff vaccines, with potential in oncology.
• The company's COVID vaccine (Nuvaxovid) is noted for its efficacy and safety, being non-mRNA.
• Partnership agreements with Sanofi and Pfizer are in place.
• UK liability is scheduled to be over by June 30, 2027, and GAVI liability by the end of 2028.

Negatives

• Share price has declined 27% from January 1, 2023, to March 31, 2026.
• Shares outstanding have increased by 96% from January 1, 2023, to March 31, 2026, resulting in significant dilution.
• Cash and Equivalents have decreased by 45% from $1.35 Billion (as of 12/31/25) to $750 million.
• Nuvaxovid achieved only approximately 1% share or ~$22 million in revenues in 2025, which is considered unfathomable and unacceptable.
• Massive R&D expenses continue, with combined non-GAAP $620 million projected for 2024-25.
• Sanofi's continued delay of the Phase 3 launch for the Covid/Influenza combo vaccine is a point of frustration.
• Management has failed to implement aggressive cost-cutting measures, with a top-heavy senior executive roster and an eight-member board.
• The company's 2026 revenue forecast is considered pessimistic, with Nuvaxovid's target US market share projected at ~10% instead of over 30%.
• An ill-advised convertible bond extension and a $50 million principal increase in outstanding convertible bonds occurred in August 2025.
• The equity short interest is elevated at approximately 30% of float, or 48 million shares.
• The equity valuation shows leadership pursuing tenure over shareholder value.
• Novavax has spent $1.35 billion in R&D alone in 2023-25, which is comparable to its current market capitalization of ~$1.3 billion.
• There is a combined ~$100 million liability from GAVI/UK.
• The equity has declined 95% in the last 5 years.

Risks

• Continued value destruction for shareholders due to operational shortcomings.
• Failure to achieve projected revenues and market share for key products like Nuvaxovid.
• Delays in critical partnership developments, such as the Sanofi COVID/Influenza combo vaccine.
• Inability to implement necessary cost-cutting measures, leading to persistent unprofitability.
• Further dilution of shareholder equity through dilutive financing activities.
• Lack of strategic conviction from the board and management, leading to 'cash hoarding' while equity underperforms.
• Sustained high short interest, indicating a lack of confidence in the company's prospects.
• Potential for continued governance issues if management and board structure are not reformed.
• The risk that shareholders may not dissent sufficiently to force leadership changes, as Shah Capital anticipates being in the minority against an entrenched board.

Future Outlook

The filing expresses a pessimistic outlook for 2026 revenue forecasts, particularly for Nuvaxovid, and criticizes the slow progress of key partnerships. Shah Capital advocates for aggressive cost-cutting and strategic financial maneuvers like retiring debt and share buybacks to improve future financial performance and shareholder value.

Management Comments

• Shah Capital states that Novavax's tenure has overseen a 'DESTRUCTION of shareholder value - a direct result of chronic operational shortcomings and failures on fiduciary duty.'
• They express surprise and frustration with Sanofi's continued delay of the Phase 3 launch of the Covid/Influenza combo vaccine.
• Shah Capital believes there is 'no justification for a top-heavy roster of senior executives and/or an eight-member Board to manage a largely passive stream of royalty and partnership revenues.'
• They view the Board's 'cash hoarding while equity massively underperforms' as a 'lack of strategic conviction.'
• Shah Capital asserts that the current equity valuation shows leadership is 'pursuing tenures and not shareholder value.'
• They argue that leadership must guide maximum profitability with combined SG&A and R&D expense spending under $100 million for 2027.
• Shah Capital believes Novavax must 'retire the outstanding convertible debt with cash on hand at the earliest, showing confidence in its superior science and positive future.'
• They suggest the company can also 'opportunistically buy back 10-20 million shares.'
• Shah Capital states that the current senior management team should be reduced by 30% and the board size reduced to five from eight, including electing new members with emphasis on pragmatic entrepreneurial experience.

Industry Context

StockSavvy.ai notes that this filing represents a significant shareholder activism event within the biotechnology and pharmaceutical sector, specifically concerning vaccine development companies. The criticisms regarding revenue generation, R&D spending relative to market cap, and partnership execution are common themes in this highly competitive and capital-intensive industry. The call for governance changes and cost discipline reflects broader investor pressure on companies to demonstrate efficient capital allocation and a clear path to profitability.

Comparison to Industry Standards

• The filing criticizes Nuvaxovid's ~1% revenue share in 2025, which is considered extremely low compared to industry standards for successful vaccine launches, especially given the billions spent on development.
• Shah Capital's target of combined SG&A and R&D expense spending under $100 million for 2027 is a significant cost-cutting goal. Many established pharmaceutical companies with similar revenue streams operate with higher expense ratios, but Novavax's situation, characterized by high R&D spend relative to market cap ($1.35B R&D vs. ~$1.3B market cap), suggests a need for drastic measures.
• The elevated short interest of ~30% of float is considerably higher than typical industry averages, indicating a strong negative sentiment from a segment of the market, potentially driven by perceived underperformance compared to peers like Pfizer and Moderna in the mRNA vaccine space.
• The proposed reduction of the board from eight to five members aligns with trends in corporate governance aimed at increasing efficiency and accountability, though board sizes vary widely across the industry based on company size and complexity.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the stated 'value destruction,' dilution, and the potential for future value creation if governance and strategic changes are implemented. The intent to vote against nominees and compensation signals a significant conflict.
• Employees: Potential impact from recommended 30% reduction in senior management, suggesting restructuring and potential job losses at the executive level.
• Creditors: The recommendation to retire convertible debt could impact creditors depending on the company's ability to meet obligations, but also signals a move towards a stronger balance sheet.
• Board of Directors: Directly targeted by the call for re-election opposition and reduction in size, indicating a loss of confidence from a major shareholder.

Next Steps

• Shareholders will vote on board nominees and executive compensation at the upcoming 2026 Annual Meeting.
• Shah Capital urges all shareholders to dissent to bring leadership to 'truly listen and follow pragmatism.'
• Shah Capital hopes for a like-minded strategic long-term investor to take a 10-20% ownership position to reshape Novavax.

Key Dates

Recommendation

While Shah Capital's activism highlights significant issues and potential for improvement, the company's core science is acknowledged as strong. The immediate recommendation is 'hold' as the outcome of the shareholder vote and potential strategic shifts are uncertain. Investors should monitor the proxy battle and management's response closely. A positive resolution could lead to a 'buy,' while continued operational failures could warrant a 'sell.'

Keywords

Novavax, Shah Capital Management, Schedule 13D, Shareholder Activism, Board Nominees, Executive Compensation, Nuvaxovid, Vaccine Development, Shareholder Value, Corporate Governance, Dilution, Revenue Forecast, Cost Cutting, Convertible Bond, Short Interest